Showing results (521-530 of 592) with videos related to

Sort By:
Pageof 60
Cancers|February 5, 2021
Bringing Onco-Innovation to Europe's Healthcare Systems: The Potential of Biomarker Testing, Real World Evidence, Tumour Agnostic Therapies to Empower Personalised MedicineDenis Horgan, Gennaro Ciliberto, Pierfranco Conte, et al.
American Journal of Cancer Research|September 2, 2015
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplificationMatteo Brunelli, Alessia Nottegar, Giuseppe Bogina, et al.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Lung Cancer (Amsterdam, Netherlands)|April 5, 2016
BE-POSITIVE: Beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: Results from a multicenter Italian observational studyTiziana Vavalà, Alessandro Follador, Marcello Tiseo, et al.
NPJ Breast Cancer|February 5, 2025
Accessible model predicts response in hormone receptor positive HER2 negative breast cancer receiving neoadjuvant chemotherapyLuca Mastrantoni, Giovanna Garufi, Giulia Giordano, et al.
JCO Precision Oncology|June 12, 2026
Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020)Alessandro Leonetti, Monica Pluchino, Roberta Minari, et al.
Clinical Lung Cancer|June 25, 2017
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE StudySara Pilotto, Antonio Rossi, Tiziana Vavalà, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 21, 2021
Sex-Based Dimorphism of Anticancer Immune Response and Molecular Mechanisms of Immune EvasionFabio Conforti, Laura Pala, Eleonora Pagan, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trialEnrica Capelletto, Maria Rita Migliorino, Alessandro Morabito, et al.
Frontiers in Oncology|July 24, 2024
Tissue- and liquid-biopsy based NGS profiling in advanced non-small-cell lung cancer in a real-world setting: the IMMINENT studyMarco Sposito, Lorenzo Belluomini, Riccardo Nocini, et al.
Pageof 60